PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
Abstract Background Immune checkpoint blockade targeting PD-1/PD-L1 has shown efficacy in several types of cancers. However, the correlation between PD-L1/PD-1 expression and the specific clinicopathological features in papillary thyroid carcinoma (PTC) has not been investigated. Methods We examined...
Main Authors: | Yanhua Bai, Dongfeng Niu, Xiaozheng Huang, Ling Jia, Qiang Kang, Fangyuan Dou, Xinqiang Ji, Weicheng Xue, Yiqiang Liu, Zhongwu Li, Qin Feng, Dongmei Lin, Kennichi Kakudo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-10-01
|
Series: | Diagnostic Pathology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13000-017-0662-z |
Similar Items
-
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
by: Janice M. Mehnert, et al.
Published: (2019-03-01) -
Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
by: Woon Won Kim, et al.
Published: (2018-01-01) -
Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis
by: Silvio Däster, et al.
Published: (2020-04-01) -
The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis
by: Yuan Tian, et al.
Published: (2021-07-01) -
Low-Dose Decitabine Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction via Modulating PD-1 Methylation in Immune Thrombocytopenia
by: Panpan Han, et al.
Published: (2021-02-01)